Fosun Pharmaceutical (600196.SH) subsidiary FXR0906 injection approved for clinical trial.

Zhixin Finance APP News, Fosun Pharma (600196.SH) announced that its controlling subsidiary Fosun Pharma Industry Development (Shenzhen) Co., Ltd. (referred to as "Fosun Pharma (Shenzhen)") recently received approval from the National Medical Products Administration to conduct clinical trials for FXR0906 injection (referred to as "FXR0906") for the treatment of hypertriglyceridemia. Fosun Pharma (Shenzhen) plans to conduct Phase I clinical research of the drug in China once the conditions are met.